Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program
Epilepsia · 2023
DOI: 10.1111/epi.17665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2023. Verfasst von Robert J Flamini und 14 weiteren Autor:innen. Beteiligte Einrichtung: PANDA Neurology, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Seizures, Cannabidiol, Epilepsy, Compassionate Use Trials. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: New York State Department of Health.
Abstract (Originalsprache)
The cannabidiol (CBD) Expanded Access Program (EAP), initiated in 2014, provided CBD (Epidiolex) to patients with treatment‐resistant epilepsy (TRE). In the final pooled analysis of 892 patients treated through January 2019 (median exposure = 694 days), CBD treatment was associated with a 46%–66% reduction in median monthly total (convulsive plus nonconvulsive) seizure frequency. CBD was well tolerated, and adverse events were consistent with previous findings. We used pooled EAP data to investigate the effectiveness of add‐on CBD therapy for individual convulsive seizure types (clonic, tonic, tonic–clonic, atonic, focal to bilateral tonic–clonic), nonconvulsive seizure types (focal with and without impaired consciousness, absence [typical and atypical], myoclonic, myoclonic absence), and epileptic spasms. CBD treatment was associated with a reduction in the frequency of convulsive seizure types (median percentage reduction = 47%–100%), and nonconvulsive seizure types and epileptic spasms (median percentage reduction = 50%–100%) across visit intervals through 144 weeks of treatment. Approximately 50% of patients had ≥50% reduction in convulsive and nonconvulsive seizure types and epileptic spasms at nearly all intervals. These results show a favorable effect of long‐term CBD use in patients with TRE, who may experience various convulsive and nonconvulsive seizure types. Future controlled trials are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PANDA Neurology, Atlanta, Georgia, USA.
- Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- University of Alabama School of Medicine, Birmingham, Alabama, USA.
- Sutter Health, Roseville, California, USA.
- Texas Children's Hospital and Baylor College of Medicine, Houston, Texas, USA.
- NYU Langone Comprehensive Epilepsy Center, New York, New York, USA.
ORCID-Profile: Robert J Flamini, Anne M Comi, E Martina Bebin, Orrin Devinsky, Shaun A Hussain, Paul D Lyons, Anup D Patel, Jillian L Rosengard, Farhad Sahebkar, Jerzy P Szaflarski
Förderung
- New York State Department of Health
Zitieren
APA
Flamini, R. J., Comi, A. M., Bebin, E. M., Chez, M. G., Clark, G., Devinsky, O., Hussain, S. A., Lyons, P. D., Patel, A. D., Rosengard, J. L., Sahebkar, F., Segal, E., Seltzer, L., Szaflarski, J. P., & Weinstock, A. (2023). Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program. Epilepsia. https://doi.org/10.1111/epi.17665
Vancouver
Flamini RJ, Comi AM, Bebin EM, Chez MG, Clark G, Devinsky O, et al. Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program. Epilepsia. 2023. doi:10.1111/epi.17665
BibTeX
@article{Flamini2023,
author = {Flamini, Robert J and Comi, Anne M and Bebin, E Martina and Chez, Michael G and Clark, Gary and Devinsky, Orrin and Hussain, Shaun A and Lyons, Paul D and Patel, Anup D and Rosengard, Jillian L and Sahebkar, Farhad and Segal, Eric and Seltzer, Laurie and Szaflarski, Jerzy P and Weinstock, Arie},
title = {Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program},
journal = {Epilepsia},
year = {2023},
doi = {10.1111/epi.17665}
}
EUVIMED